Morgan Stanley Gives Color on Johnson & Johnson's in Pharma Review

According to a recent article from Morgan Stanley, Johnson & Johnson JNJ has estimated a lead in the pharma industry for total drug sales launched in 2009- 11. JNJ reported these sales have totaled over $1.1 billion. In the report, Morgan Stanley said, "We expect this momentum to continue as the company works past key 2008-11 patent cliffs and pipeline launches accelerate. In all, we project pharma growth to rebound to a 4.2% CAGR over 2011-14 from a -3.4% CAGR over 2007-10." Johnson & Johnson closed yesterday at $65.51.